Hemophilia Market

The global Hemophilia market size was valued at USD 4.4 billion in 2020 and is anticipated to expand at a CAGR of 8.2% during the forecast period, 2021-2028. The growth of the market is attributed to the rising research and development initiatives, particularly on the identification of therapeutic agents.

Get Free Sample Report

Hemophilia is an inherited genetic disorder which impairs the ability of the body to produce blood clots. This results in the bleeding for long periods of time after any injury for the body, easy bruising, and a huge risk in the bleeding of inside joints connected to the vital internal organs including the brain. The symptoms of Hemophilia can only be noticed after the injury or during the treatment of patients during accidents. This bleeding into the joints can result permanent damage whereas the bleeding in the brain causes long term complications such as seizures, low level of consciousness, and acute headaches. Prevention can be done by the removal of an egg, the fertilization of the egg, and the testing plus diagnosis of the embryo before it is transferred to the uterus. Another form of treatment lies in the replacement of the missing factors of blood clotting.

According to the World Health Organization or the WHO, a census report upon Hemophilia concluded that one in every 10,000 people have Hemophilia, and the number of occurrences will only increase in the coming years. The COVID-19 pandemic has reduced the growth of the global Hemophilia market initially. However, upon further studies, researchers and scientists found out that the coronavirus has the viral gene of accelerating illness of the hosts. Basically, a patient of Hemophilia was more susceptible to the COVID-19 virus than that of a healthy person. This steered to hospitals, clinics, and healthcare laboratories to focus more on the diagnosis of Hemophilia for the prevention and treatment of diseases and this led to its market growth in the later stages of this pandemic.

Market Trends, Drivers, Restraints, and Opportunities

• Increase in spending and investing by both the government authorities and private investors plus companies towards the diagnosis of Hemophilia is the primary reason for the projection of boosting the market growth during the forecast period, 2021-2028.
• There has been a significant increase in the research and development activities of Hemophilia to commence the early stages of screening neonates which can become a major factor boosting the market growth.
• High prices for the treatment of Hemophilia and high cost of services from the company’s perspective is anticipated to hinder the global Hemophilia market growth. This becomes extremely difficult to function in developing countries such as India, South Africa and Brazil where there is limited healthcare infrastructure with regards to Hemophilia.
• The treatment program for Hemophilia highly varies from individual based on genetic factor and the environment the patient is brought upon. For some people, Hemophilia can be manageable, but this cannot be said for other patients. This uncertainty can hamper the Hemophilia market growth.
• R&D investment and technological advancement are expected to offer significant opportunities for the market players. Researchers and scientists have understood the significant cost factor in the treatment of Hemophilia and realized that they can innovate new methodologies for this treatment fee to be feasible for the patients. The “MyAccess Cost-Share Program” was introduced by the CSL Behring board and the WHO for the USA patients to provide treatment costing up to USD 11,000.

Scope of the Report

The report on the global Hemophilia market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Global Hemophilia Market Segment Insights

Hemophilia A segment is projected to represent a large market share
On the basis of types, the global Hemophilia market is divided into Hemophilia A, Hemophilia B, Hemophilia C, and others. The Hemophilia A segment is expected to constitute the major share of the market in 2019. The major reason attributing to this market growth is the high occurrence of this disease, which is four times more than the next highest occurring disease, Hemophilia B .

Meanwhile the Hemophilia B segment is anticipated to grow with a significant CAGR during the forecast period. Hemophilia B has approximately 20% of its cases globally and it is only rising from this period owing to the unhealthy lifestyle people have been indulging upon.

On-Demand segment is estimated to signify the largest market share
Based on treatments, the global Hemophilia market is bifurcated into On-Demand and Prophylaxis. The On-Demand segment is expected to constitute the major share of the market in 2019. The major reason attributing to this market growth is the frequency of this treatment involving simple procedures which can be executed in any environment or on any patient.

Meanwhile the Prophylaxis segment is anticipated to grow with a significant CAGR during the forecast period, 2021-2028. The accuracy and precision of this method is far greater than that of the On-Demand treatment and can be feasible in the forecast period.

Replacement segment is anticipated to register a huge market share
On the basis of therapies, the global Hemophilia market is divided into replacement Therapy, ITI Therapy, and gene Therapy. The replacement segment is expected to constitute the major share of the market in 2019. The major reason attributing to this market growth is low cost along with high efficacy. This product, however, is currently expected to lose sales during the forecast period, 2021-2028 as researchers and scientists have been able to find new methodologies involving lower cost and higher efficacy.

Meanwhile the gene segment is anticipated to grow with a significant CAGR during the forecast period. With the latest methodologies and research studies revolving gene therapy, the scientists believe that Hemophilia can be treated and cured using the gene therapy.

Get Free Sample Report

North America is anticipated to dominate the market
On the basis of regions, the global Hemophilia market is categorized as Asia Pacific, North America, Latin America, Europe and Middle East & Africa. The market in North America is expected to constitute a major share of 44.3% in 2019. This regional market growth can be attributed to the growing research & development expenditure along with the rising in adoption of the latest technology. The demand of Hemophilia treatment is increasing rapidly in this region due to the presence of the major market players in the market, an advantage other regions do not have. The cost of expenditure is significantly lower in North America than that of other economies. However, the market in Asia Pacific is anticipated to expand at a significant CAGR during the forecast period, 2021-2028, as they have prioritized the cost-efficiency perspective of Hemophilia combined with their growing population.

Segments

• Hemophilia A
• Hemophilia B
• Hemophilia C
• Others

• On-Demand
• Prophylaxis

• Replacement Therapy
• ITI Therapy
• Gene Therapy

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

• Shire (Baxalta)
• CSL Behring
• Pfizer Inc
• Bayer AG
• BioMarin
• Spark Therapeutics Inc
• Genzyme Corporation
• Sanofi Inc
• Chugai Pharmaceutical Co Ltd
• Novo Nordisk A/S
• Octapharma AG

Competitive Landscape

Major players competing in the global Hemophilia market are Shire (Baxalta); CSL Behring; Pfizer Inc; Bayer AG; BioMarin; Spark Therapeutics Inc; Genzyme Corporation; Sanofi Inc; Chugai Pharmaceutical Co Ltd; Novo Nordisk A/S; and Octapharma AG. These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. Spark Therapeutics Inc, developed the SPK-8011 in 2019, used commonly for the treatment of Hemophilia Type A and as of now is currently undergoing clinical trials for the Type B and Type C diagnostics. From the acquisition perspective, Sanofi Inc acquired Bioverativ, a US based Hemophilia specialist for the cost of USD 11.6 billion to increase the strength of Sanofi Inc in the global Hemophilia market.